Combination therapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with triple-negative breast cancer (meaning the cancer cells don't have receptors for estrogen, progesterone, or HER2).
- You have a tumor sample that can be tested for a protein called PD-L1.
- Your cancer is stage IIA to IIIC and has not spread to other parts of the body.
- You have not had chemotherapy or targeted therapy for advanced breast cancer before.
- You are in good overall health (ECOG score 0-2) and your major organs are working well.
- You are willing to use birth control during the study and for 8 weeks after the last treatment dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether adding a probiotic (Lactobacillus Johnsonii) to standard chemotherapy and immunotherapy can help people with certain advanced solid tumors that have stopped responding to prior immunotherapy. It may help your immune system work better against the cancer.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.